Induction Chemotherapy Prior to Radio-immunotherapy in Head and Neck Cancer Stage III/IV - a Methodical Trial
The purpose of the trial is to determine the feasibility of an induction chemotherapy with radio-immunotherapy in patients with head and neck cancer stage III/IV
Head and Neck Cancer
DRUG: Docetaxel|DRUG: Cisplatin|DRUG: 5-FU|RADIATION: Radiotherapy|DRUG: Cetuximab
Locoregional tumour control, Time without progression of locoregional disease, locoregional recurrence of disease or death from any cause after one year., 12 months
Response rate, PET-CT or CT, RECIST criteria, 24 months|Progression free survival, PFS is calculated from start of therapy until disease progression or death from any cause., 24 months|Overall survival, OS is calculated from start of therapy to death from any cause., 24 months|Toxicities, The highest grade of a toxicity per patient is included in the analysis, 24 months
3 Cycles of: Docetaxel 75 mg/m2 on d1, Cisplatin 75 mg/m2 on d1, 5-FU 750 mg/m2 on days 1-5 as continuous i.v. infusion, Duration of 1 cycle: 21 days;

Followed by Cetuximab 400 mg/m2, Start of radiotherapy: 1 week after the first application of Cetuximab, During radiotherapy (35 x 2 Gy): Cetuximab 250 mg/m2 weekly, Up to 8 applications of Cetuximab.